PURDUE
OFFICE OF TECHNOLOGY COMMERCIALIZATION

Innovation Infosheet
Downloaded August 8, 2022

Modified Bis-amide Derivatives as Protease inhibitors for treatment of Covid-19

Track Code: 2021-GHOS-69206

Categories:
- Chemistry and Chemical Analysis
- Pharmaceuticals

Keywords:
- Chemistry and Chemical Analysis
- Coronavirus
- COVID-19
- Drug Development
- Medicinal Chemistry
- Pharmaceuticals
- Therapeutics

Researchers at Purdue University have developed a new class of noncovalent functionalized bis-amide inhibitors for treatment of Covid-19.

There remains an ongoing global health pandemic which has now affected over 170 million people to date and there is no available therapeutic option. The compounds developed by Purdue researchers in this disclosure are newer modified versions of bis-amide derivatives that have demonstrated potent inhibitory effect on SARS-CoV-2 enzyme, 3CLpro. These inhibitors have been evaluated in immunocytochemical and cellular assays against Covid-19 infections.

Advantages:
-Potent Covid-19 Antiviral Properties
-Improved Drug-Like Features

Potential Applications:
-Treatment of SARS-CoV-2
-Pharmaceutical Research and Development
-Pandemic Control

Technology Validation:
The bis-amide compounds potently inhibited SARS-CoV-2 in in vitro studies and immunocytochemistry assays.

People:

- Ghosh, Arun K (Project leader)
- Mesecar, Andrew D
- Mitsuya, Hiroaki

Intellectual Property:

Application Date: November 30, 2021
Type: PCT-Gov. Funding
Country of Filing: WO
Patent Number: (None)
Issue Date: (None)

Application Date: December 1, 2020
Type: Provisional-Gov. Funding
Country of Filing: United States
Patent Number: (None)
Issue Date: (None)

Contact OTC:

Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org